Thus, targeting the IGF-1/IGF-1R axis, including the HDAC/IGF-1 epigenetic pathway, may have therapeutic benefits in the treatment of hypoxia-induced PPHN. Here, IGF1 is linked to persistent fetal circulation syndrome.